严时佳

Publications

2026

Engineering bacterial nanosyringes for regional immune recalibration at the oral barrier

Wan AH, Liang H, Yan S, Xiao M, Liu R, Wan G*

Oral Sci Homeost Med. 2026 May; 2(2): 9610055.·2026·DOI

Dual-system engineered bacteria and dendritic cells enable precise intratumoral IL-12 delivery and potent antitumor immunity.

Deng Y#, Liang H#, Wan AH#, Liu C#, Yan S#, Li J, Xiao M, Zhou Q, Liu R, Zhang Z, Zhang H, Cheng H, Fu C, Yao Q, Fang J, Neumann S, Wang Q, Huang J*, Wang Z*, Wan G*.

Cell Rep Med. 2026 Jun 16;7(6):102801.·2026·DOI

TeroACT: A terpenoid bioactivity landscape and discovery platform.

Shen X#, Yan S#, Kang X, Xu K, Jian Y, Zeng T, Wan G*, Wu R*.

Acta Pharm Sin B. 2026 Mar;16(3):1233-1249.·2026·DOI

HNRNPA2B1 Orchestrates Immune Evasion in Colorectal Cancer by Rewiring Tumor-Immune Cell Interactions and Suppressing CD8+ T-cell Infiltration.

Liu C, Liang H, Wang P, Xiao M, Zheng Y, Yan S, Deng Y, Liu R, Wan AH, Wang Z*, Lu X*, Song W*, He W*, Wan G*.

Cancer Immunol Res. 2026 Jan 8;14(1):60-76.·2026·DOI

2025

Non-stoichiometric Sodium Chloride Reprograms Ionic Homeostasis to Enhance Antitumor Immunity.

Wang C#, Deng Y#, Liang H#, Wan AH#, Yan S, Xiao M, Liu C, Fang J, Wang Z*, Wan G*.

MedComm (2020). 2025 Nov 29;6(12):e70534.·2025·DOI

Proviral Integration Site for Moloney Murine Leukemia Virus 2 Suppresses Fibronectin 1 to Drive Adhesion Loss and Epithelial-Mesenchymal Transition in Multiple Myeloma.

Mai J#, Liang H#, Wan AH#, Xiao M#, Zhang H, Deng Y, Yan S, Wan G*, Zheng Y*.

ACS Pharmacol Transl Sci. 2025 Oct 27;8(11):3835-3843.·2025·DOI

Decoding the m6A epitranscriptomic landscape for biotechnological applications using a direct RNA sequencing approach.

Liu C#, Liang H#, Wan AH#, Xiao M#, Sun L#, Yu Y, Yan S, Deng Y, Liu R, Fang J, Wang Z*, He W*, Wan G*.

Nat Commun. 2025 Jan 18;16(1):798.·2025·DOI

TarIKGC: A Target Identification Tool Using Semantics-Enhanced Knowledge Graph Completion with Application to CDK2 Inhibitor Discovery.

Shen X, Yan S, Zeng T, Xia F, Jiang D, Wan G, Cao D*, Wu R*.

J Med Chem. 2025 Jan 23;68(2):1793-1809.·2025·DOI

2024

A multidimensional platform of patient-derived tumors identifies drug susceptibilities for clinical lenvatinib resistance.

Sun L, Wan AH, Yan S, Liu R, Li J, Zhou Z, Wu R, Chen D, Bu X, Ou J, Li K, Lu X, Wan G*, Ke Z*.

Acta Pharm Sin B. 2024 Jan;14(1):223-240.·2024·DOI

Galectin-7 Induction by EHMT2 Inhibition Enhances Immunity in Microsatellite Stability Colorectal Cancer.

Sun L, Liu R, Wu ZJ, Liu ZY, Wan AH, Yan S, Liu C, Liang H, Xiao M, You N, Lou Y, Deng Y, Bu X, Chen D, Huang J, Zhang X, Kuang DM, Wan G*.

Gastroenterology. 2024 Mar;166(3):466-482.·2024·DOI

2023

N6-methyladenosine demethylase FTO enhances chemo-resistance in colorectal cancer through SIVA1-mediated apoptosis.

Lin Z, Wan AH, Sun L, Liang H, Niu Y, Deng Y, Yan S, Wang QP, Bu X, Zhang X, Hu K*, Wan G*, He W*.

Mol Ther. 2023 Feb 1;31(2):517-534.·2023·DOI

2022

Tryptophan and tumor immunity

Zhang C, Yan S, Wan G*.

Acta Pharm Sin. 2022, 57(9): 2580-2589·2022·DOI

The immunomodulatory effect of lactic acid within the tumor microenvironment

Ge W, Yan S, Wan G*.

Acta Pharm Sin. 2022, 57(9): 2570-2579·2022·DOI

2021

Loss-of-Function Genetic Screening Identifies Aldolase A as an Essential Driver for Liver Cancer Cell Growth Under Hypoxia.

Niu Y, Lin Z, Wan A, Sun L, Yan S, Liang H, Zhan S, Chen D, Bu X, Liu P, Chen C, He W, Lu X, Wan G*.

Hepatology. 2021 Sep;74(3):1461-1479.·2021·DOI

Tumor-associated macrophages in immunotherapy.

Yan S, Wan G*.

FEBS J. 2021 Nov;288(21):6174-6186.·2021·DOI

RNA-binding protein RALY reprogrammes mitochondrial metabolism via mediating miRNA processing in colorectal cancer.

Sun L#, Wan A#, Zhou Z, Chen D, Liang H, Liu C, Yan S, Niu Y, Lin Z, Zhan S, Wang S, Bu X, He W, Lu X*, Xu A*, Wan G*.

Gut. 2021 Sep;70(9):1698-1712.·2021·DOI

2020

Hypoxia⁃induced HIF⁃1α down⁃regulates FUT4 expression under hypoxia in colon cancer via inducing hsa⁃ miRNA⁃23a⁃3p

He W, Li Q, Yan S, Wan G*.

J Pract Med. 2020, 36(8): 1035-1040·2020·DOI

New Strategy for COVID-19: An Evolutionary Role for RGD Motif in SARS-CoV-2 and Potential Inhibitors for Virus Infection.

Yan S, Sun H, Bu X*, Wan G*.

Front Pharmacol. 2020 Jun 12;11:912.·2020·DOI

2019

The mechanism and research progress of drug resistance of PD-1/PD-L1 immunotherapy in tumors

Yan S, Sun L, Wan G*.

Acta Pharm Sin. 2019, 54(10): 1728-1734·2019·DOI

Review on clinical research progress of immunotherapy in liver cancer

Yan S, Liu X, Wan G*.

Acta Pharm Sin. 2019, 54(10): 1749-1754·2019·DOI